An interventional study of Digoxin alarm in Drug-Related Side Effects and Adverse Reaction and Digoxin Overdose, sponsored by Consorci Sanitari de l'Alt Penedès i Garraf. Active, not recruiting at 2 sites in Spain. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2026-10-29.
Sponsored by Consorci Sanitari de l'Alt Penedès i Garraf · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies in Drug-Related Side Effects and Adverse Reactions with a site in Spain — 6 open to participants now, 8 under way, none of them phase 3. Drug-Related Side Effects and Adverse Reactions · Spain.
Among the 16 studies in Drug-Related Side Effects and Adverse Reactions with a site in Spain, this one is the 2nd largest by planned enrollment of the 11 interventional ones that give a count, is one of 3 that started in 2025, is one of 5 with no phase, and was the 12th registered.
449 studies on the registry are indexed under Drug-Related Side Effects and Adverse Reactions; 77 are open to participants now.
Browse Drug-Related Side Effects and Adverse Reactions studies →6 of the 16 studies in Drug-Related Side Effects and Adverse Reactions with a site in Spain are open now. Recruiting first, the newest first:
Adcytherix SAS · Sites in Spain, Australia
Ages 18+
Eli Lilly and Company · Sites in Spain, United States, Australia and 7 more countries
Ages 18+
Fundación Pública Andaluza para la Investigación Biomédica Andalucía Oriental · Sites in Spain
Ages 18+
Parc Sanitari Pere Virgili · Sites in Spain
Ages 65+
Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León · Sites in Spain
Ages 65+
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 56 Drug-Related Side Effects and Adverse Reactions studies recruiting now, 38 (68%) set no upper age limit and 15 (27%) stop at 75 or younger; 15 take children under 18; 4 take healthy volunteers.
This study: 65 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 4 · Phase 3 1
First in 2001; this study’s year is marked. 3 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 5,954 is above the median of 108 across 262 interventional studies indexed under Drug-Related Side Effects and Adverse Reactions.
Median enrollment 290 across the 11 interventional studies, 1,000 across the 5 observational. Of the 6 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 16 have an industry lead sponsor. The 10 most frequent:
Consorci Sanitari de l'Alt Penedès i Garraf is the lead sponsor of 45 studies on the registry; 21 are open to participants now.
Consorci Sanitari de l'Alt Penedès i Garraf has 1 study filed under Drug-Related Side Effects and Adverse Reactions — fewer than ten, so there is no comparison to draw.
3 of the studies in Drug-Related Side Effects and Adverse Reactions with a site in Spain that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07169851Eli Lilly and CompanyA Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer | 2026-12 |
| NCT07582887Fundación Pública Andaluza para la Investigación Biomédica Andalucía OrientalImpact of Genetic Variants on the Toxicity of Antibody-Drug Conjugates in Locally Advanced or Metastatic Breast Cancer: The Role of the UGT1A1 Gene as a Predictive Biomarker of Therapeutic Response | 2026-12-31 |
| NCT07008144Consorci Sanitari de l'Alt Penedès i GarrafIntroducing Electronic Alerts to Reduce Inappropriate Digoxin Prescribing in Older Adults | 2027-06-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 16 studies in Drug-Related Side Effects and Adverse Reactions with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The intervention consists of introducing computerized alerts into the electronic medical record of the CSAPG (MIRA software), which are triggered when a physician prescribes digoxin at a dose higher than the recommended amount (more than 0.125 mg/day).
The main objective of this study is to evaluate the effectiveness of a visible computerized alert aimed at physicians responsible for hospitalized elderly patients who have been prescribed digoxin at a dose higher than 0.125 mg/day (the recommended dose), in reducing the number of patients receiving inappropriate digoxin doses.
Intervention This quasi-experimental pre-post intervention study evaluates the effectiveness of computerized alerts integrated into the CSAPG electronic health record system (MIRA software). These alerts are triggered when a physician prescribes digoxin at a dose higher than the recommended 0.125 mg/day for elderly patients.
Study Objective The main goal is to assess whether these alerts reduce the number of elderly hospitalized patients receiving inappropriate digoxin dosages.
Study Design and Duration The study will last 18 months in total, with a 12-month data collection period at each site (6 months before and 6 months after the intervention).
Sample Size and Population To detect a 25% reduction in inappropriate digoxin prescriptions with 80% power and a 0.05 alpha risk, the study requires 2,977 patients in both the pre- and post-intervention groups. Inclusion criteria include hospitalized men and women aged 65 and older. No patient exclusions are anticipated.
Statistical Analysis The primary analysis will compare the proportion of patients receiving digoxin doses above the recommended level before and after the intervention using the Chi-square test.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
In this group, the outcome will be measured before the intervention is implemented at the center
In this group, the outcome will be measured after the intervention is implemented at the center
Other: Digoxin alarm
A computerized alert will be integrated into the CSAPG electronic health record system (MIRA software). These alerts will be triggered when a physician prescribes digoxin at a dose higher than the recommended 0.125 mg/day for elderly patients.
Proportion of elderly inpatients receiving inappropriate digoxin doses
Proportion of patients aged 65 and older who are prescribed digoxin at a dose higher than 0.125 mg/day during hospitalization. The outcome compares this proportion between the pre-intervention and post-intervention periods to evaluate the effectiveness of a computerized alert integrated into the electronic medical record system (MIRA).
Time frame: From baseline to hospital discharge, as much 3 months
Plan to share: Yes — IPD (without personal identification data) could be shared by requirement from other researchers after the end of the study, and only for research purposes and previous approval of promotor center of the study (CSAPG). Anyway, Spanish and European Union legal policy about data protection will strictly be followed (IPD will not be transferred outside European Union).
Supporting information: Study protocol
Time frame: After publication of main results of the study.
Access criteria: IPD will be shared only for scientific research purposes and following the Spanish and European Union normative law about data protection. The requirements will be directed to the IP of the study. The IP will evaluate the request to verify and evaluate the data that is requested and the purposes for which it is requested. Next, the IP will transfer the request to the promotor center the study for the final decision.
Started Dec 2025 (actual). Primary completion is estimated for Jun 2027, 17 months after the start.
Of 71 non-industry interventional studies with no phase under Drug-Related Side Effects and Adverse Reactions, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 43. This study's planned 17 months is below that.
Counting every sponsor, half of 73 studies reached it within 26 months; a quarter within 12 and three quarters within 43.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 29, 2026: primary completion Nov 2026 → Jun 2027 and completion Nov 2026 → Jun 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Drug-Related Side Effects and Adverse Reactions →
Consorci Sanitari de l'Alt Penedès i Garraf